TABLE 1.

Patient demographic and clinical characteristics

Characteristic	Value(s)
	NTM-positive patients (n = 468) (%)	NTM-negative patients (n = 9,427) (%)
Age, mean ± SD	54.5 ± 20.7	50.5 ± 21.7
Sex
Female	240 (51.3)	4,546 (48.2)
Male	228 (48.7)	4,881 (51.8)
Predisposeda	255 (54.5)	2,805 (29.8)
NTM test site
Lung	310 (66.3)	2,990 (31.7)
Blood and cardiovascular	13 (2.8)	490 (5.2)
Genitourinary	6 (1.3)	79 (0.8)
Skin and musculoskeletal	6 (1.3)	753 (8)
Gastrointestinal	3 (0.6)	516 (5.5)
Sinus	3 (0.6)	45 (0.5)
Lymphatic	1 (0.2)	47 (0.5)
Central nervous system	0	360 (3.8)
Other	47 (10.0)	2,489 (26.4)
Missing/unknown	79 (16.9)	1,658 (17.6)
NTM species
M. avium complex	213 (45.5)
M. chelonae/M. abscessus complexb	69 (14.7)
M. fortuitum	42 (9.0)
M. terrae	36 (7.7)
M. mucogenicum	20 (4.3)
M. gordonae	16 (3.4)
M. kansasii	15 (3.2)
Other	14 (3.0)
Unknown/missing	43 (9.2)

^aDefined using ICD-9 and ICD-10 diagnosis codes for immunocompromising conditions and structural lung disease that may predispose to NTM infection (2, 31 – 34) (Table S1).

^bThe clinical microbiology laboratory did not differentiate these species during part of the study period.